Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load - Full Text View

Sponsor:	National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:	New York Presbyterian Hospital
Information provided by:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT00013663

Purpose

The purpose of this study is to determine if HIV-specific canarypox vaccine and/or interleukin-2 (IL-2) will control viral load (amount of HIV in the blood) after HIV treatment is withdrawn for a certain time period.

Condition	Intervention	Phase
HIV Infections	Biological: ALVAC(2)120(B,MN)GNP (vCP1452) Drug: Aldesleukin	Phase II

Study Type:	Interventional
Study Design:	Masking: Double-Blind Primary Purpose: Treatment
Official Title:	A Randomized Controlled Study Testing the Efficacy of Immunotherapies to Control Plasma HIV RNA Concentrations Upon Interruption of Highly Active Antiretroviral Therapy

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency

MedlinePlus related topics: HIV/AIDS HIV/AIDS Medicines

Drug Information available for: Aldesleukin

U.S. FDA Resources

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:

Mean log10 viral load for each experimental group from the average of 5 values obtained during Weeks 21 to 25 (8 to 12 weeks following HAART interruption

Secondary Outcome Measures:

Proportion of participants who relapse during the first 12 weeks following stopping of HAART
length of time to the termination of Step II among participants
changes in frequency, activation state, and HIV-specific functional capacity of T and NK cells in blood, as monitored by expression of intracellular cytokines during the first 12 weeks after stopping HAART, with respect to termination of Step II

Estimated Enrollment:

92

Detailed Description:

Step I: In addition to continuing HAART, patients are randomized into 1 of the following 4 arms:

A: Immunization placebo; B: Immunization with the canarypox HIV-vaccine (vCP1452); C: Daily low-dose IL-2 + immunization placebo; or D: Daily low-dose IL-2 + canarypox HIV-vaccine (vCP1452). Patients on Arms A, B, C, and D receive vaccine (or vaccine placebo) injections at Weeks 0, 4, 8, and 12. Patients on Arms C and D receive IL-2 by self-injection. HAART is not provided as part of this study.

Step II: Patients on all arms (A, B, C, and D) who meet inclusion criteria advance to Step II and interrupt HAART for a minimum of 12 weeks. The efficacy of these immunological therapies will be determined by monitoring the dynamics of viral rebound upon cessation of antiviral therapy. After 12 weeks of Step II, patients whose viral load remains below 30,000 copies/ml remain on Step II, off HAART, and continue weekly viral load monitoring. Patients will not terminate Step II or resume HAART unless and until their viral load increases to more than 30,000 copies/ml on 3 successive determinations, or their CD4 count decreases to less than 200 cells/mm3 or less than 50 percent of the baseline CD4+ T cell concentration on 2 successive occasions.

Eligibility

Ages Eligible for Study:	19 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

Are HIV-positive.
Are more than 18 years old.
Have been receiving their current HAART (2 or more anti-HIV drugs in combination) for more than 6 consecutive months.
Have a CD4 count of 200 cells/microL or more within the 12 months prior to entering the study and 400 cells/microL or more on 2 occasions at least 2 weeks apart within 30 days of entry.
Have never had a viral load higher than 2 million molecules/ml and have had the viral load controlled with HAART to less than 50 molecules/ml on 2 occasions at least 2 weeks apart within 30 days of entry.
Have not had virologic failure on the current HAART regimen.
Have a negative urine pregnancy test within 14 days of entering the study.

Exclusion Criteria

Patients will not be eligible for this study if they:

Have a current AIDS-defining illness.
Have had failure of the current HAART regimen (viral load higher than 10,000 molecules/ml).
Have a history of using agents affecting the immune system.
Have active uncontrolled heart disease.
Have had IL-2 therapy within 4 weeks of entering the study.
Have received other treatment that affects the immune system within 4 weeks of entry.
Have a history of a cancer requiring chemotherapy.
Have untreated thyroid disease, within 4 weeks of entering the study.
Have uncontrolled allergic disorders or autoimmune diseases, including asthma, inflammatory bowel disease, and psoriasis.
Abuse substances that may interfere with the ability to follow study requirements.
Are allergic to eggs.
Have hepatitis B or hepatitis C.
Are pregnant or breast-feeding.
Work in close contact with canaries, such as a job at breeding farms or bird shops.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00013663

Locations

United States, New York
New York Hosp - Cornell Med Ctr
New York, New York, United States, 10021

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

New York Presbyterian Hospital

Investigators

Principal Investigator:

Kendall A. Smith, MD

Division of Immunology, Department of Medicine, Weill Medical College, Cornell University

More Information

Additional Information:

Click here for more information about aldesleukin This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier:	NCT00013663 History of Changes
Obsolete Identifiers:	NCT00034099
Other Study ID Numbers:	B012, 0900-397
Study First Received:	March 27, 2001
Last Updated:	June 29, 2006
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

Virus Replication
HIV-1
AIDS Vaccines
RNA, Viral
Avipoxvirus
Genetic Vectors

Viral Load
aldesleukin
Antiretroviral Therapy, Highly Active
HIV Therapeutic Vaccine
Treatment Interruption

Additional relevant MeSH terms:

HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases

Slow Virus Diseases
Aldesleukin
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on February 12, 2012